SINTX Chief Scientific Officer Retires and Director of R&D Steps Into Leadership Role
01 January 2022 - 1:00AM
SINTX Technologies, Inc. (www.sintx.com) (NASDAQ: SINT) (“SINTX” or
the “Company”), an original equipment manufacturer of advanced
ceramics, announced today its Chief Scientific Officer, Dr. Bryan
J. McEntire, will be retiring at the end of 2021 after 17 years
with the company. Dr. Ryan Bock will move into the role of Vice
President of Research and Development (R&D) to take on the
leadership of SINTX’s R&D activities. Following retirement, Dr.
McEntire will continue supporting SINTX Technologies in the role of
Emeritus Scientific Officer.
Dr. McEntire has worked in the advanced ceramic
industry for 46 years and has co-authored more than 130 technical
papers and presentations on ceramic materials, processing, and
characterization. During his time at SINTX, he has been responsible
for research and development, product development, testing and
validation, manufacturing, and quality control for orthopedic
implants produced from silicon nitride. Before joining SINTX,
McEntire held various senior positions in notable ceramics and
materials companies including Applied Materials, Saint-Gobain
Industrial Ceramics Corporation, Norton/TRW Ceramics, and
Ceramatec. He was elected as a Fellow of the American Society in
2012 and served as an invited short-course lecturer on Forming of
Ceramics at the Annual Meeting of the American Ceramic Society from
1986 to 1995.
“Dr. McEntire has been a tremendous asset and
friend to SINTX for nearly two decades,” said Dr. Sonny Bal,
President, and CEO, SINTX Technologies. “While we’re sad to see him
go, we are excited that he’ll maintain involvement through an
advisory role.”
“It’s been both a privilege and a pleasure to
work with and for the great men and women of SINTX in the
development of advanced ceramic solutions for biomedical,
industrial, aerospace, and armor markets,” said Dr. Bryan J.
McEntire. “I couldn’t have ended my career with a more admirable
organization, having strong management leadership, and outstanding
technical and manufacturing talent. I wish them all the best in
their future endeavors, and I hope to be of service to them in my
new advisory role.”
Currently Director of R&D, Dr. Bock will
continue biomaterial development efforts in addition to expanding
application-focused research into antipathogenic and technical
ceramic products as he steps into the role of Vice President of
R&D when Dr. McEntire retires. Dr. Bock has supported SINTX
through a variety of roles for 13 years and has an extensive
background in advanced ceramics, colloid & surface science, and
biomaterials.
“I am looking forward to leading SINTX’s R&D
efforts which include rich collaborations with academic and
industrial research groups around the world along with focused,
application-driven research performed by our skilled and dedicated
internal team,” said Dr. Ryan Bock, Director of R&D, SINTX
Technologies. “It has been my great honor to have Dr. McEntire as a
mentor and colleague during many years of biomaterial development
activities, including the discovery of novel silicon nitride
properties that enable SINTX to provide differentiated products
into an ever-expanding variety of market spaces. His expertise and
advice will be highly valued as we continue to find new
applications for advanced ceramic materials.”
About SINTX Technologies, Inc.
SINTX Technologies is an OEM ceramics company
that develops and commercializes advanced ceramics for medical and
non-medical applications. The core strength of SINTX Technologies
is the manufacturing, research, and development of ceramics for
external partners. The Company presently manufactures silicon
nitride powders and components in its FDA registered, ISO
13485:2016 certified, and ASD9100D certified manufacturing
facility.
For more information on SINTX Technologies
or its silicon nitride material platform, please
visit www.sintx.com.
Forward-Looking Statements
This press release contains forward-looking
statements within the meaning of the Private Securities Litigation
Reform Act of 1995 (PSLRA) that are subject to a number of risks
and uncertainties. Risks and uncertainties that may cause such
differences include, among other things: our products may not prove
to be as effective as other products currently being commercialized
or to be commercialized in the future by competitors; risks
inherent in manufacturing and scaling up to commercial quantities
while maintaining quality controls; volatility in the price of
SINTX’s common stock; the uncertainties inherent in new product
development, including the cost and time required to commercialize
such product(s); market acceptance of our products once
commercialized; SINTX’s ability to raise funding and other
competitive developments. Readers are cautioned not to place undue
reliance on the forward-looking statements, which speak only as of
the date on which they are made and reflect management’s current
estimates, projections, expectations and beliefs. There can be no
assurance that any of the anticipated results will occur on a
timely basis or at all due to certain risks and uncertainties, a
discussion of which can be found in SINTX’s Risk Factors disclosure
in its Annual Report on Form 10-K, filed with the Securities and
Exchange Commission (SEC) on March 22, 2021, and in SINTX’s other
filings with the SEC. SINTX disclaims any obligation to update any
forward-looking statements. SINTX undertakes no obligation to
publicly revise or update the forward-looking statements to reflect
events or circumstances that arise after the date of this
report.
Business Inquiries for SINTX:SINTX
Technologies801.839.3502IR@sintx.com
Media Inquiries for SINTX: Amanda Barry
Director of PR and ContentThe Summit Group abarry@summitslc.com
SiNtx Technologies (NASDAQ:SINT)
Historical Stock Chart
From Apr 2024 to May 2024
SiNtx Technologies (NASDAQ:SINT)
Historical Stock Chart
From May 2023 to May 2024